期刊文献+

鼠疫耶尔森杆菌蛋白YPO1996的融合表达与鉴定

Expression and identification of Yersinia pestis fusion protein YPO1996
原文传递
导出
摘要 目的在比较蛋白质组结果的基础上选择并构建pET32a-ypo1996,表达鼠疫耶尔森杆菌(Yersinia pestis)特异的假想蛋白YPO1996重组蛋白(rYPO1996),为新鼠疫耶尔森杆菌诊断试剂的研究提供备选抗原。方法根据鼠疫菌CO92株全基因组序列设计引物,用PCR方法扩增目的基因YPO1996,将其定向插入表达载体pET32a(+)上,转化至大肠埃希菌BL21(DE3),用IPTG诱导,使重组质粒在工程菌中稳定高效地表达带组氨酸标签的融合蛋白,并亲和纯化该目的蛋白。通过SDS-PAGE方法对表达的蛋白产物进行初步分析,并用Western blot分析其抗原性。结果单、双酶切鉴定及DNA测序显示,目的基因YPO1996成功连接到表达载体pET32a(+)上,SDS-PAGE显示表达产物分子质量单位约为53.11 ku,与预期值相符。重组蛋白经Western blot鉴定,能被兔抗免疫鼠疫菌EV株血清识别。结论成功构建了pET32a-ypo1996重组基因原核表达系统,表达的重组蛋白rYPO1996具有较好的可溶性及抗原性,可作为研发新型鼠疫耶尔森杆菌诊断试剂的备选抗原。 Objective To construct the recombinant plasmid pET32a-ypo1996 based on Yersinia pestis comparative proteome and express the protein rYPO1996 in order to develop a new method of diagnosing Y.pestis.Methods Primers were designed according to the YPO1996 gene sequence of Y.pestis strain CO92.The target DNA fragments of YPO1996 were amplified by polymerase chain reaction(PCR),and the products were inserted directionally into a pET32a(+) vector.The recombinant plasmid was transformed into E.coli BL21(DE3) and inducted by IPTG.The fusion protein was effectively expressed and purified.The expressed protein was analyzed by SDS-PAGE and Western blot. Results The target gene YPO1996 had been inserted successfully into pET32a(+),and the results of SDS-PAGE showed that the expression product was about 53.11 ku as predicted.The fusion protein rYPO1996 performed well in terms of solubility and can be recognized by antibodies against the Y.pestis strain(EV strain) in Western blot.Conclusion The new pET32a-ypo1996 plasmid is successfully constructed in a prokaryotic expression system,and the protein rYPO1996 showed satisfactory solubility and antigenicity.It may be an acceptable candidate antigen for the diagnosis of Y.pestis infection.
出处 《中国病原生物学杂志》 CSCD 2009年第3期166-168,186,共4页 Journal of Pathogen Biology
基金 国家"十一五"863计划生物和医药技术领域2006年专题目标导向课题项目(No.2006AA02Z4A7)
关键词 鼠疫耶尔森杆菌 YPO1996 抗原 克隆 表达 Yersinia pestis YPO1996 antigen clone expression
  • 相关文献

参考文献7

  • 1Perry RD, Fetherstone JD. Yersinia pestis etiological agent of plague[J]. Clin Microbiol Rev, 1997,10(1) : 35-66.
  • 2Anonymous. Human plague in 1994[J]. Wkly Epidemiol Ree, 1996,71(22) :165-168.
  • 3Heath DG, Anderson GW Jr, Mauro JM, et al. Protection against experimental bubonic and pneumonic plague by a recombinant capsular F12V antigen fusion protein vaecine[J]. Vaccine, 1998, 16(11P12) : 1131-1137.
  • 4Williamson ED,Eley SM,Griffin KF,et al. A new improved subunit vaccine for plague:the basis of protection[J]. FEMS Immunol Med Microbiot, 1995,12 (3P4) : 223-230.
  • 5Williamson ED, Eley SM, Stagg AJ, et al. A single dose subunit vaccine protects against pneumonic plague[J]. Vaccine, 2001,19 (4P5) : 566-571.
  • 6Lewis JP,Babiuk LA. DNA vaccines: a review[J]. Adv Virus Res, 1999,54: 129-188.
  • 7黄顺军,王希良,李名扬,罗德炎,阳幼荣,马丽娟.鼠疫F1-V融合蛋白在大肠杆菌中的高效表达及鉴定[J].免疫学杂志,2004,20(z1):152-155. 被引量:10

二级参考文献7

  • 1[2]Andrews GP, Heath DG, Anderson GW, et al. Fraction 1capsular antigen(F1) purification from Yersinia pestis CO92and an Escherichia coli recombinant strain and efficacy against lethal plague challenge [ J ]. Infect Immun, 1996, 64 (6):2 180-2 187.
  • 2[3]Titball RW, Howells AM, Oyston PC, et al. Expression of the Yersinia pestis capsular antigen (F1 antigen) on the surface of the aroA mutant of Salmonella typhimurium induces high levels of protection against plague [J]. Infect immun,1997,65(5): 1 926 - 1 930.
  • 3[4]Leary SE, Williamson ED, Griffin KF, et al. Active immunization with recombinant V antigen from Yersinia pestis protect mice against plague[J]. Infect Immunol, 1995, 63(8):2 854 - 2 858.
  • 4[5]Williamson ED, Sharp G J, Eley SM, et al. Local and system immune response to a microencapsulated sub-unit vaccine for plague[J]. Vaccine, 1996,14(17/18): 1 613- 1 619.
  • 5[6]Eyles JE,Williamson ED, Spiers ID, et al. Protection studies following bronchopulmonary and intramuscular immunization with Y. pestis F1 and V sub-unit vaccine coencapsulated in biodegradable microspheres: a comparsion of efficacy [J].Vaccine, 2000,18(28): 3 266 - 3 271.
  • 6[7]Leary SE,Griffin KF, Gannory HS, et al. Expression of an F1/V fusion protein in attenuated Salmonella typhimurium and protection of mice against plague [ J]. Microbial Pathogenesis, 1997, 23(3): 167 - 179.
  • 7[8]Health DG, Anderson JW, Mauro JM, et al. Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine [J]. Vaccine,1998, 16 (11/12): 1 131- 1 137.

共引文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部